scholarly journals Investigating neural correlates of mild cognitive impairment using estimated clinical status from neuropsychological test battery: LASI‐DAD

2020 ◽  
Vol 16 (S10) ◽  
Author(s):  
Brenton James Keller ◽  
Jinkook Lee ◽  
Arthur W Toga ◽  
Jorge Jovicich ◽  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychological Test ◽  
Clinical Status ◽  
Neural Correlates ◽  
Test Battery ◽  
Neuropsychological Test Battery

PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDY

2018 ◽  
pp. 1-9
Author(s):  
J.E. Harrison ◽  
D.M. Rentz ◽  
H.R. Brashear ◽  
H.M. Arrighi ◽  
M.T. Ropacki ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychological Test ◽  
Cognitive Change ◽  
Test Battery ◽  
Change Over Time ◽  
Neuropsychological Test Battery ◽  
Over Time

Background: The Neuropsychological Test Battery (NTB) is a combination of widely used clinical neuropsychological tests measuring memory and executive function and was designed to overcome some of the limitations of the traditionally used Alzheimer’s disease Assessment Scale – Cognitive subscale (ADAS-Cog). A previously reported account indicated high levels of NTB reliability in patients with mild-to-moderate Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Objectives: We examined capacity of the Neuropsychological Test Battery (NTB) and its component subtests to measure cognitive change over time. Correlations with other cognitive and functional assessments were also determined. Design, Settings, Participants: This was a multicentre, prospective, non-interventional, longitudinal cohort study involving patients with mild-to-moderate AD (n=196), MCI (n=70), or cognitively normal control participants (NC, n=75). Intervention: The NTB, as well as other Clinical Outcome Assessments including, ADAS-Cog, other cognitive measures, functional/behavioral questionnaires, health outcome questionnaires, and resource utilization tools were administered. Results: Mean change from baseline for the NTB composite score and the six individual NTB subtests showed greater reductions in performance over time in the AD and MCI groups, compared with NC group. The ADAS-Cog was found to be more sensitive to change than the NTB in all three populations. Conclusions: The NTB showed high correlation with the ADAS-Cog and appears to be a sensitive and reliable assessment tool for measuring cognitive decline in patients with mild-to-moderate AD. However, the ADAS-Cog was found to be more sensitive to change over time in both the AD and MCI populations.

Parietal Signs and Sinister Prognosis in Dementia

1991 ◽  
Vol 158 (3) ◽  
pp. 358-361 ◽  
Author(s):  
Ronan O'Carroll ◽  
Janice Whittick ◽  
Elizabeth Baikie
Keyword(s):  
Cognitive Impairment ◽  
Parietal Lobe ◽  
Neuropsychological Test ◽  
Test Battery ◽  
Full Time ◽  
Neuropsychological Test Battery

Thirty elderly demented subjects were assessed in 1985 using a neuropsychological test battery which included tests of parietal lobe function that are allegedly predictive of outcome. Four years later, 29 out of the 30 subjects were followed up. Twelve had died. There were no differences between survivors and deceased in terms of age, pre-morbid intelligence, years of full-time education, or scores on parietal tests. However, proportionally more of the women had died, and those subjects with more global cognitive impairment in 1985 were significantly more likely to have died by 1989. Those who scored lower on an aphasia measure in 1985 were more likely to have died. None of the variables differentiated between survivors and deceased Alzheimer subjects.

scholarly journals Investigation of a neuropsychological screen for chemo-fog

2011 ◽  
Vol 5 (4) ◽  
pp. 205 ◽  
Author(s):  
Lea Ann Ouimet ◽  
Angela Stewart ◽  
Barbara Collins ◽  
Dwayne Schindler ◽  
Catherine Bielajew
Keyword(s):  
Cognitive Impairment ◽  
Neuropsychological Tests ◽  
Clinical Utility ◽  
Cognitive Impairments ◽  
Neuropsychological Test ◽  
Test Battery ◽  
Neuropsychological Test Battery ◽  
Increased Risk ◽  
Chemo Fog ◽  
Risk Of Misclassification

Research on chemotherapy-induced cognitive impairment (the term ‘‘chemo-fog’’ is used by many investigators) supports the occurrence of subtle declines in function for a subset of recipients. Identification of vulnerable individuals via comprehensive neuropsychological batteries is complicated due to their lack of clinical utility and increased risk of misclassification. The goal of this paper was to evaluate the ability of a reduced battery to detect chemotherapy-related cognitive impairments. Data from our previous study (Ouimet et al. J Clin Exp Neuropsychol 31:73–89, 2009) were used to compare a comprehensive neuropsychological test battery comprising 23 tests with a reduced battery consisting of a subset of nine tests. A standardized regression-based approach revealed that a comparable numbers of participants were identified by both batteries, suggesting that individuals vulnerable to chemotherapy-induced cognitive impairment can be identified by a more selective battery. Further work is needed to clarify the neuropsychological tests most sensitive to detecting impairments associated with chemotherapy so that assessment batteries can be limited to these tests.

Sign in / Sign up

Export Citation Format

Share Document